All In Biotech

Drug Trial Radar · NCT05126758

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

106

Actual

Start

Jun 22, 2022

Primary completion

Jun 18, 2025

Study completion Mar 2027

Sponsor

Lead sponsor
Capricor Inc.Industry
Sponsor type
Industry
First posted
Nov 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months of the study. All participants will be eligible to receive 4 doses of deramiocel for an additional 12 months as part of an open-label extended assessment period. After completion of the first open-label extension (Months 12-24), subjects who have completed Month 24 are eligible to continue onto a Long-Term Open-Label Extension period that will provide treatment with deramiocel until commercial availability, or until sponsor's decision to terminate the trial, or the participant withdraws consent.

Conditions

  • Muscular Dystrophies
  • Muscular Dystrophy, Duchenne
  • Muscular Disorders, Atrophic
  • Muscular Diseases
  • Neuromuscular Diseases
  • Genetic Diseases, X-Linked
  • Genetic Diseases, Inborn
  • Nervous System Diseases

Interventions

  • DeramiocelBiological

    Cardiosphere-Derived Cells (CDCs)

  • PlaceboBiological

    Placebo

  • Cardiac magnetic resonance imagingDiagnostic test

    Cardiac magnetic resonance imaging is performed to assess cardiac function

  • Cardiac magnetic resonance imaging with contrastDiagnostic test

    Cardiac magnetic resonance imaging with contrast to assess late gadolinium enhancement (LGE) in Cohort B participants

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the upper limb functionTime frame: At Month 12

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • UCSD Altman Clinical and Translational Research Institute

    La Jolla, California

  • Children's Hospital of Los Angeles, Division of Neurology

    Los Angeles, California

  • University of California, Davis

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Rare Disease Research, LLC

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Boston Children's Hospital

    Boston, Massachusetts

  • University of Missouri Health Care

    Columbia, Missouri

  • Saint Louis Children's Hospital

    St Louis, Missouri

  • Rare Disease Research NC LLC

    Hillsborough, North Carolina

  • Akron Children's Hospital

    Akron, Ohio

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Health Specialty Care Pavilion

    Dallas, Texas

  • University of Utah Hospital

    Salt Lake City, Utah

  • University of Virginia Children's Hospital

    Charlottesville, Virginia

  • Seattle Children's

    Seattle, Washington

  • Children's Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.